DOI: 10.6084/m9.figshare.29482947
title: Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor

description: Tenosynovial giant-cell tumor (TGCT) is a rare condition characterized by pain, stiffness, and limited range of motion. Pexidartinib is the first regulatory-approved systemic therapy for adult patients with symptomatic TGCT not amenable for surgery. This study evaluated symptom improvement in patients who newly initiated pexidartinib. A longitudinal, observational study collected data on patient-reported outcomes, demographics, disease history, pexidartinib dosing, and clinicians’ perspective. Identified from the TURALIO Risk Evaluation and Mitigation Strategy (REMS) program, 80 patients who newly initiated pexidartinib between April and October 2022 received a study invitation, and 14 completed the baseline assessment; mean (SD) age was 39.8 (13.60) years, 50.0% were female, and most common tumor sites were in the lower extremities (71.4%). By the end of study follow-up (May 2023), 11 patients completed some PRO assessments at follow-up, and median time on pexidartinib was 7.5 months. Results showed a trend of reduction in pain and stiffness and improvement in physical functioning. Overall, 80% (8/10) endorsed moderately high treatment satisfaction with pexidartinib treatment. Findings from this study provided real-world evidence of an association between pexidartinib initialization and symptom improvements among patients with symptomatic TGCTs from the patients’ and clinicians’ perspective. What is this study about? Tenosynovial giant-cell tumor (TGCT) is a rare disease with approximately 11–50 new cases diagnosed per million people per year. TGCT can affect any joints in the body and has a disabling impact on physical functioning. This article reports the symptoms changes and treatment satisfaction of 14 patients who started treatment with pexidartinib to treat TGCT in the real world. What were the study results? The study surveyed patients up to approximately 12 months following their first dose of pexidartinib and found that the treatment was associated with pain reduction, reduced stiffness in the joints and improvement of overall physical functioning in most patients. Based on physicians’ notes and radiological imaging of 10 patients, half of these patients’ overall symptoms were much improved since initiating pexidartinib. While patients were generally satisfied with their treatment with pexidartinib, not all patients reported improvements in pain, stiffness or physical functioning. What do these results mean? The results of this study are consistent with findings from previous studies on patients treated with pexidartinib and added real-world evidence to support the use of pexidartinib in patients with TGCT whose condition is not likely to improve with surgery. A critical review of all available evidence and an analysis of data aggregated from published studies may allow more concrete conclusions to be drawn on the role of pexidartinib in addressing unmet medical needs in real-world clinical practice. A PDF version of this infographic is available as supplemental material. To view the interactive version, please download and open the PDF in Adobe Acrobat.